Skip to Main Content

Advertisement

Skip Nav Destination

Obinutuzumab plus Bendamustine Followed by Obinutuzumab Maintenance Prolongs Overall Survival Compared with Bendamustine Alone in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma: Updated Results of the GADOLIN Study

Blood (2016) 128 (22): 615.
Currently there are no citedby results. Try again later.
Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement